2025 Scientific Sessions Late-Breaking Abstracts

ASE invites you to submit your late-breaking clinical trial or large-scale study for a chance to present in 36th Annual Scientific Sessions!




Content and Format Guidelines

  • Word limit – Abstracts are limited to 2,000 words. This includes the text, but not the title or authors.
  • Tables/Graphics – The use of up to three (3) tables and/or graphics is encouraged if they are relevant to the research submitted. These images can either be embedded within your abstract file or submitted as separate attachments.
  • Author Block - Abstracts must include the first and last names for all authors. Do not list authors by initial only.
  • Abbreviations – A maximum of five (5) unique abbreviations is allowed within the body of the abstract.
  • Format – Content must be structured into the following four (4) sections:
  • Background:
  • Methods:
  • Results:
  • Conclusion:
  • Clarity of expression will be considered in the review process. The overall quality of language used should assure comprehension by the reader.
  • Do not include:
  • References for credits.
  • Names or personal information of any patient participating in the study or trial. If you do, the abstract will not be considered for presentation.
  • Authors or institutions in the title.
  • Proofread abstracts carefully to avoid errors.

Submission Deadline - June 13, 5:00PM EST


Select
Caret IconCaret symbol
Select
Caret IconCaret symbol

It is the policy of ASE to ensure balance, independence, objectivity, and scientific rigor in all its educational activities. All presenters participating in any ASE activity are expected to disclose to the audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. Financial interest or other relationships may include grants or research support, consultant, stockholder, member of a speakers’ bureau, owner or employee of a company. Presenters are required to make disclosure of any financial interest/arrangement or affiliation with any organization(s) that could be perceived as a real or apparent conflict of interest in the context of their presentation subject matter.


For presenters at the ASE 36th Annual Scientific Sessions to be in compliance with this policy, oral presenters will be required to disclose at the beginning of their presentation. Poster presenters will be required to include disclosure information on their posted presentation materials.

Select
Caret IconCaret symbol

Within the past 12 months, myself and/or my co-authors, and/or a spouse/significant other have received support from or had a relationship with the following commercial interests (indicate all that apply). Disclosure should include relationships in any amount.


The ACCME defines a commercial interest as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exception of nonprofit or government organizations and non health-care related companies. Providers of clinical services directly to patients are not considered a commercial interest.


For each author, please enter their name and the name of the commercial interest in the box below. If an author has a relationship with more than one commercial interest, please list all relationships.

Please include your last name and abstract title in the file name.

Drag and drop files here or
Privacy Notice|Report Abuse